
The U.S. Food and Drug Administration (FDA) convened a Type A meeting with Verrica Pharmaceuticals (NASDAQ:VRCA) regarding the course of action for the clearance of its drug candidate VP-102.
The Type A meeting was held on Jun 27th, 2022, in connection with the way forward for the resubmission and potential approval of the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum).